MedTrace Logo

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

NCT04571437 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2020-10-01

No results posted yet for this study

Summary

A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine metronomic combined with Letrozole

DRUG

Letrozole 2.5mg

Letrozole daily alone

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mariam Saleh, M.D · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-10-31
Completion
2022-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571437 on ClinicalTrials.gov